Skip to main content

Staff Profile

Dr Jérémie Nsengimana

Senior Lecturer in Biostatistics

  • Address: Population Health Sciences Institute
    Faculty of Medical Sciences
    Newcastle University
    Ridley 1 building, Level 4
Background

Jérémie Nsengimana is Senior Lecturer of Biostatistics in the Population Health Sciences Institute, Faculty of Medical Sciences. He holds a PhD from the Université Catholique de Louvain, Belgium (UCLLouvain) and has previously worked at the University of Leeds School of Medicine, Leeds, UK (2004-2020), and the International Agency for Research on Cancer, Lyon, France (2003-2004). Jérémie's research focuses on efficient design and analysis of preclinical studies with a particular interest in biomarker and drug target discovery. He is a member of the Testicular Cancer Consortium (https://www.med.upenn.edu/tecac/) and the Melanoma Genetics Consortium (GenoMEL).

 

Supervised PhDs

Dr Rohit Thakur (2015 -2019): Developing statistical and bioinformatic analysis of genomic data from tumours 

Dr Joanna Poźniak (2015 -2019): Transcriptomic variation in primary melanoma in immunological pathways related to survival

Lucy Godson (2020-): Machine learning integration of molecular and imaging data in cancer outcome prediction

Pela Okorie (2022-): Prevalence, determinants, and experiences of mental health conditions amongst COVID-19 survivors during the first wave of COVID-19 pandemic in Nigeria: a mixed-method study.

Ayat Bashir (2023-): Improving diagnosis and management of patients with diabetes secondary to chronic pancreatitis


Google scholar: here 

Researchgate:  here

Scopus: here

 

 

Research

Efficient design and analysis in preclinical/translational research. Current projects include testicular cancer etiology using familial data, biomarkers in melanoma and liver cancer, COVID-19 pandemic and mental health.

Teaching

I teach postgraduate Medical Statistics & supervise research projects.

MMB8101 module lead (250 MRes students)

MSC8002, MSC8003, MSC8004 (teaching statistics component and support to research project)

HSC8036 (contribution)

Publications

  • Articles

    • Godson L, Alemi N, Nsengimana J, Cook GP, Clarke EL, Treanor D, Bishop DT, Newton-Bishop J, Gooya A, Magee D. Immune subtyping of melanoma whole slide images using multiple instance learning. Medical Image Analysis 2024, 93, 103097.
    • Castro MV, Barbero G, Villanueva BM, Nsengimana J, Newton-Bishop J, Illescas E, Quezada MJ, Lopez-Bergami P. ROR2 promotes epithelial to mesenchymal transition by hyperactivating ERK in melanoma. Journal of Cell Communication and Signaling 2023, 17(1), 75-88.
    • Suresh S, Rabbie R, Garg M, Lumaquin D, Huang T-H, Montal E, Ma Y, Cruz NM, Tang X, Nsengimana J, Newton-Bishop J, Hunter MV, Zhu Y, Chen K, de Stanchina E, Adams DJ, White RM. Identifying the Transcriptional Drivers of Metastasis Embedded within Localized Melanoma. Cancer Discovery 2023, 13(1), 194-215.
    • Tagore M, Hergenreder E, Perlee SC, Cruz NM, Menocal L, Suresh S, Chan E, Baron M, Melendez S, Dave A, Chatila WK, Nsengimana J, Koche RP, Hollmann TJ, Ideker T, Studer L, Schietinger A, White RM. GABA regulates electrical activity and tumour initiation in melanoma. Cancer Discovery 2023, 13(10), 2270–2291.
    • Davies J, Muralidhar S, Randerson-Moor J, Harland M, O'Shea S, Diaz J, Walker C, Nsengimana J, Laye J, Mell T, Chan M, Appleton L, Birkealv S, Adams DJ, Cook GP, Ball G, Bishop DT, Newton-Bishop JA. Ulcerated melanoma: Systems biology evidence of inflammatory imbalance towards pro-tumourigenicity. Pigment Cell and Melanoma Research 2022, 35(2), 252-267.
    • Papaiz DD, Rius FE, Ayub ALP, Origassa CS, Gujar H, Pessoa DO, Reis EM, Nsengimana J, Newton-Bishop J, Mason CE, Weisenberger DJ, Liang G, Jasiulionis MG. Genes regulated by DNA methylation are involved in distinct phenotypes during melanoma progression and are prognostic factors for patients. Molecular Oncology 2022, 16(9), 1913-1930.
    • Castaneda-Garcia C, Iyer V, Nsengimana J, Trower A, Droop A, Brown KM, Choi J, Zhang T, Harland M, Newton-Bishop JA, Bishop DT, Adams DJ, Iles MM, Robles-Espinoza CD. Defining novel causal SNPs and linked phenotypes at melanoma-associated loci. Human Molecular Genetics 2022, 31(17), 2845-2856.
    • Grasso C, Popovic M, Isaevska E, Lazzarato F, Fiano V, Zugna D, Pluta J, Weathers B, D'Andrea K, Almstrup K, Anson-Cartwright L, Bishop DT, Chanock SJ, Chen C, Cortessis VK, Dalgaard MD, Daneshmand S, Ferlin A, Foresta C, Frone MN, Gamulin M, Gietema JA, Greene MH, Grotmol T, Hamilton RJ, Haugen TB, Hauser R, Karlsson R, Kiemeney LA, Lessel D, Lista P, Lothe RA, Loveday C, Meijer C, Nead KT, Nsengimana J, Skotheim RI, Turnbull C, Vaughn DJ, Wiklund F, Zheng T, Zitella A, Schwartz SM, McGlynn KA, Kanetsky PA, Nathanson KL, Richiardi L. Association Study between Polymorphisms in DNA Methylation-Related Genes and Testicular Germ Cell Tumor Risk. Cancer Epidemiology, Biomarkers & Prevention 2022, 31(9), 1769-1779.
    • Garg M, Couturier D-L, Nsengimana J, Fonseca NA, Wongchenko M, Yan Y, Lauss M, Jonsson GB, Newton-Bishop J, Parkinson C, Middleton MR, Bishop DT, McDonald S, Stefanos N, Tadross J, Vergara IA, Lo S, Newell F, Wilmott JS, Thompson JF, Long GV, Scolyer RA, Corrie P, Adams DJ, Brazma A, Rabbie R. Tumour gene expression signature in primary melanoma predicts long-term outcomes. Nature Communications 2021, 12(1), 1137.
    • Pessoa DO, Rius FE, Papaiz DD, Ayub ALP, Morais AS, de Souza CF, da Paixão VF, Setubal JC, Newton-Bishop J, Nsengimana J, Azevedo H, Reis EM, Jasiulionis MG. Transcriptional signatures underlying dynamic phenotypic switching and novel disease biomarkers in a linear cellular model of melanoma progression. Neoplasia 2021, 23(4), 439-455.
    • Shelton M, Anene CA, Nsengimana J, Roberts W, Newton-Bishop J, Boyne JR. The role of CAF derived exosomal microRNAs in the tumour microenvironment of melanoma. Biochimica et Biophysica Acta (BBA) Reviews on Cancer 2021, 1875(1), 188456.
    • Bi O, Anene CA, Nsengimana J, Shelton M, Roberts W, Newton-Bishop J, Boyne JR. SFPQ promotes an oncogenic transcriptomic state in melanoma. Oncogene 2021, 40, 5192-5203.
    • Castro MV, Barbero GA, Villanueva MB, Grumolato L, Nsengimana J, Newton-Bishop J, Illescas E, Quezada MJ, Lopez-Bergami P. ROR2 has a protective role in melanoma by inhibiting Akt activity, cell cycle progression and proliferation. Journal of Biomedical Science 2021, 28(1), 76.
    • Juraleviciute M, Nsengimana J, Newton-Bishop J, Hendriks GJ, Slipicevic A. MX2 mediates establishment of interferon response profile, regulates XAF1, and can sensitize melanoma cell to targeted therapy. Cancer Medicine 2021, 10(8), 2840-2854.
    • Polubothu S, Zecchin D, Al-Olabi L, Lionarons DA, Harland M, Horswell S, Thomas AC, Hunt L, Wlodarchak N, Aguilera P, Brand S, Bryant D, Carrera C, Chen H, Elgar G, Harwood CA, Howell M, Larue L, Loughlin S, MacDonald J, Malvehy J, Barberan SM, da Silva VM, Molina M, Morrogh D, Moulding D, Nsengimana J, Pittman A, Puig-Butillé JA, Parmar K, Sebire NJ, Scherer S, Stadnik P, Stanier P, Tell G, Waelchli R, Zarrei M, Puig S, Bataille V, Xing Y, Healy E, Moore GE, Di WL, Newton-Bishop J, Downward J, Kinsler VA. Inherited duplications of PPP2R3B predispose to nevi and melanoma via C21orf91-driven proliferative phenotype. Genetics in Medicine 2021, 23(9), 1636-1647.
    • Pluta J, Pyle LC, Nead KT, Wilf R, Li M, Mitra N, Weathers B, DAndrea K, Almstrup K, Anson-Cartwright L, Benitez J, Brown CD, Chanock S, Chen C, Cortessis VK, Ferlin A, Foresta C, Gamulin M, Gietema JA, Grasso C, Greene MH, Grotmol T, Hamilton RJ, Haugen TB, Hauser R, Hildebrandt MAT, Johnson ME, Karlsson R, Kiemeney LA, Lessel D, Lothe RA, Loud JT, Loveday C, Martin-Gimeno P, Meijer C, Nsengimana J, Quinn DI, Rafnar T, Ramdas S, Richiardi L, Skotheim RI, Stefansson K, Turnbull C, Vaughn DJ, Wiklund F, Wu X, Yang D, Zheng T, Wells AD, Grant SFA, Rajpert-De Meyts E, Schwartz SM, Bishop DT, McGlynn KA, Kanetsky PA, Nathanson KL, The Testicular Cancer Consortium. Identification of 22 susceptibility loci associated with testicular germ cell tumors. Nature Communications 2021, 12, 4487.
    • Campbell NR, Rao A, Hunter MV, Sznurkowska MK, Briker L, Zhang M, Baron M, Heilmann S, Deforet M, Kenny C, Ferretti LP, Huang TH, Perlee S, Garg M, Nsengimana J, Saini M, Montal E, Tagore M, Newton-Bishop J, Middleton MR, Corrie P, Adams DJ, Rabbie R, Aceto N, Levesque MP, Cornell RA, Yanai I, Xavier JB, White RM. Cooperation between melanoma cell states promotes metastasis through heterotypic cluster formation. Developmental Cell 2021, 56(20), 2808-2825.
    • Emran AI, Nsengimana J, Punnia-Moorthy P, Schmitz U, Gallagher S, Newton-Bishop J, Tiffen J, Hersey P. Study of the female sex survival advantage in melanoma- a focus on X-linked epigenetic regulators and immune responses in two cohorts. Cancers 2020, 12(8), 2082.
    • Juraleviciute M, Pozniak J, Nsengimana J, Harland M, Randerson-Moor J, Wernhoff P, Bassarova A, Oy GF, Troen G, Florenes VA, Bishop DT, Herlyn M, Newton-Bishop J, Slipicevic A. MX 2 is a novel regulator of cell cycle in melanoma cells. Pigment Cell and Melanoma Research 2020, 33(3), 446-457.
    • Azevedo H, Pessoa GC, de Luna Vitorino FN, Nsengimana J, Newton-Bishop J, Reis EM, da Cunha JPC, Jasiulionis MG. Gene co-expression and histone modification signatures are associated with melanoma progression, epithelial-to-mesenchimal transition and metastasis. Clinical Epigenetics 2020, 12, 127.
    • Maurichi A, Miceli R, Eriksson H, Newton-Bishop J, Nsengimana J, Chan M, Hayes AJ, Heelan K, Adams D, Patuzzo R, Barretta F, Gallino G, Harwood C, Bergamaschi D, Bennett D, Lasithiotakis K, Ghiorzo P, Dalmasso B, Manganoni A, Consoli F, Mattavelli I, Barbieri C, Leva A, Cortinovis U, Espeli V, Mangas C, Quaglino P, Ribero S, Broganelli P, Pellacani G, Longo C, Del Forno C, Borgognoni L, Sestini S, Pimpinelli N, Fortunato S, Chiarugi A, Nardini P, Morittu E, Florita A, Cossa M, Valeri B, Milione M, Pruneri G, Zoras O, Anichini A, Mortarini R, Santinami M J. Factors affecting sentinel node metastasis in thin cutaneous melanomas: development and external validation of a predictive nomogram. Journal of Clinical Oncology Journal 2020, 38(14), 1591-1601.
    • Close HJ, Stead LF, Nsengimana J, Reilly KA, Droop A, Wurdak H, Mathew RK, Corns R, Newton-Bishop J, Melcher AA, Short SC, Cook GP, Wilson EB. Expression profiling of single cells and patient cohorts identifies multiple immunosuppressive pathways and an altered NK cell phenotype in glioblastoma. Clinical and Experimental Immunology 2020, 200(1), 33-44.
    • Muralidhar S, Filia A, Nsengimana J, Pozniak J, O'Shea SJ, Diaz JM, Harland M, Randerson-Moor JA, Reichrath J, Laye JP, Van Der Weyden L, Adams DJ, Bishop DT, Newton-Bishop J. Vitamin D–VDR signaling inhibits Wnt/b-catenin–mediated melanoma progression and promotes antitumor immunity. Cancer Research 2019, 79(23), 5986-5998.
    • Thakur R, Laye JP, Lauss M, Diaz JMS, O'Shea SJ, Poźniak J, Filia A, Harland M, Gascoyne J, Randerson-Moor JA, Chan M, Mell T, Jönsson G, Timothy Bishop D, Newton-Bishop J, Barrett JH, Nsengimana J. Transcriptomic Analysis Reveals Prognostic Molecular Signatures of Stage I Melanoma. Clinical Cancer Research 2019, 25(24), 7424-7435.
    • Filia A, Droop A, Harland M, Thygesen H, Randerson-Moor J, Snowden H, Taylor C, Diaz JMS, Pozniak J, Nsengimana J, Laye J, Newton-Bishop JA, Bishop DT. High-Resolution Copy Number Patterns From Clinically Relevant FFPE Material. Scientific Reports 2019, 9(1), 8908.
    • Pozniak J, Nsengimana J, Laye JP, O'Shea SJ, Diaz JMS, Droop AlastairP, Filia A, Harland M, Davies JR, Mell T, Randerson-Moor JA, Muralidhar S, Hogan SA, Freiberger SN, Levesque MP, Cook GP, Bishop DT, Newton-Bishop J. Genetic and environmental determinants of immune response to cutaneous melanoma. Cancer Research 2019, 79(10), 2684-2696.
    • Varaljai R, Wistuba-Hamprecht K, Seremet T, Diaz JMS, Nsengimana J, Sucker A, Griewank K, Placke J-M, Horn PA, Neuhoff N, Shannan B, Chauvistre H, Vogel FCE, Horn S, Becker JC, Newton-Bishop J, Stang A, Neyns B, Weide B, Schadendorf D, Roesch A. Application of circulating cell-free tumor DNA profiles for therapeutic monitoring and outcome prediction in genetically heterogeneous metastatic melanoma. JCO Precision Oncology 2019, 3.
    • Nsengimana J, Laye J, Filia A, O'Shea S, Muralidhar S, Pozniak J, Droop A, Chan M, Walker C, Parkinson L, Gascoyne J, Mell T, Polso M, Jewell R, Randerson-Moor J, Cook GP, Timothy Bishop D, Newton-Bishop J. β-Catenin-mediated immune evasion pathway frequently operates in primary cutaneous melanomas. Journal of Clinical Investigation 2018, 128(5), 2048-2063.
    • Litchfield K, Loveday C, Levy M, Dudakia D, Rapley E, Nsengimana J, Bishop DT, Reid A, Huddart R, Broderick P, Houlston RS, Turnbull C. Large-scale Sequencing of Testicular Germ Cell Tumour (TGCT) Cases Excludes Major TGCT Predisposition Gene. European Urology 2018, 73(6), 828-831.
    • Del Castillo Velasco-Herrera M, van der Weyden L, Nsengimana J, Speak AO, Sjoberg MK, Bishop DT, Jonsson G, Newton-Bishop J, Adams DJ. Comparative genomics reveals that loss of lunatic fringe (LFNG) promotes melanoma metastasis. Molecular Oncology 2018, 12(2), 239-255.
    • Metri R, Mohan A, Nsengimana J, Pozniak J, Molina-Paris C, Newton-Bishop J, Bishop D, Chandra N. Identification of a gene signature for discriminating metastatic from primary melanoma using a molecular interaction network approach. Scientific Reports 2017, 7, 17314.
    • Litchfield K, Levy M, Orlando G, Loveday C, Law PJ, Migliorini G, Holroyd A, Broderick P, Karlsson R, Haugen TB, Kristiansen W, Nsengimana J, Fenwick K, Assiotis I, Kote-Jarai Z, Dunning AM, Muir K, Peto J, Eeles R, Easton DF, Dudakia D, Orr N, Pashayan N, Bishop DT, Reid A, Huddart RA, Shipley J, Grotmol T, Wiklund F, Houlston RS, Turnbull C. Identification of 19 new risk loci and potential regulatory mechanisms influencing susceptibility to testicular germ cell tumor. Nature Genetics 2017, 49(7), 1133-1140.
    • Puig-Butille JA, Gimenez-Xavier P, Visconti A, Nsengimana J, Garcia-Garcia F, Tell-Marti G, Escamez MJ, Newton-Bishop J, Bataille V, Rio M, Dopazo J, Falchi M, Puig S. Genomic expression differences between cutaneous cells from red hair color individuals and black hair color individuals based on bioinformatic analysis. Oncotarget 2017, 8(7), 11589-11599.
    • Fang J, Jia J, Makowski M, Xu M, Wang Z, Zhang T, Hoskins JW, Choi J, Han Y, Zhang M, Thomas J, Kovacs M, Collins I, Dzyadyk M, Thompson A, O'Neill M, Das S, Lan Q, Koster R, Stolzenberg-Solomon RS, Kraft P, Wolpin BM, Jansen PWTC, Olson S, McGlynn KA, Kanetsky PA, Chatterjee N, Barrett JH, Dunning AM, Taylor JC, Newton-Bishop JA, Timothy Bishop D, Andresson T, Petersen GM, Amos CI, Iles MM, Nathanson KL, Landi MT, Vermeulen M, Brown KM, Amundadottir LT, Canzian F, Kooperberg C, Arslan AA, Bracci PM, Buring J, Duell EJ, Gallinger S, Jacobs EJ, Kamineni A, Van Den Eeden S, Klein AP, Kolonel LN, Li D, Olson SH, Risch HA, Sesso HD, Visvanathan K, Zheng W, Albanes D, Austin MA, Boutron-Ruault M-C, Bueno-De-Mesquita HB, Cotterchio M, Gaziano JM, Giovannucci EL, Goggins M, Gross M, Hassan M, Helzlsouer KJ, Holly EA, Hunter DJ, Jenab M, Kaaks R, Key TJ, Khaw K-T, Krogh V, Kurtz RC, LaCroix A, Le Marchand L, Mannisto S, Patel AV, Peeters PHM, Riboli E, Shu X-O, Sund M, Thornquist M, Tjonneland A, Tobias GS, Trichopoulos D, Wactawski-Wende J, Yu H, Yu K, Zeleniuch-Jacquotte A, Hoover R, Hartge P, Fuchs C, Chanock SJ, Stevens V, Albanes D, Caporaso NE, Brennan P, McKay J, Wu X, Hung RJ, McLaughlin JR, Bickeboller H, Risch A, Wichmann E, Houlston RS, Mann G, Hopper J, Aitken J, Armstrong B, Giles G, Holland E, Kefford R, Cust A, Jenkins M, Schmid H, Puig S, Aguilera P, Badenas C, Barreiro A, Carrera C, Gabriel D, Xavier PG, Iglesias-Garcia P, Malvehy J, Mila M, Pigem R, Potrony M, Puig Butille J-A, Tell-Marti G, Hayward NK, Martin NG, Montgomery G, Duffy DL, Whiteman DC, MacGregor S, Calista D, Landi G, Minghetti P, Arcangeli F, Bertazzi PA, Ghiorzo P, Bianchi-Scarra G, Pastorino L, Bruno W, Andreotti V, Queirolo P, Spagnolo F, MacKie R, Lang J, Gruis N, Van Nieuwpoort FA, Out C, Bergman W, Kukutsch N, Bavinck JNB, Bakker B, Van Der Stoep N, Ter Huurne J, Van Der Rhee H, Bekkenk M, Snels D, Van Praag M, Brochez L, Gerritsen R, Crijns M, Vasen H, Janssen B, Ingvar C, Olsson H, Jonsson G, Borg A, Harbst K, Nielsen K, Zander AS, Molven A, Helsing P, Andresen PA, Rootwelt H, Akslen LA, Paillerets BB-D, Demenais F, Avril M-F, Chaudru V, Jeannin P, Lesueur F, Maubec E, Mohamdi H, Bossard M, Vaysse A, Boitier F, Caron O, Caux F, Dalle S, Dereure O, Leroux D, Martin L, Mateus C, Robert C, Stoppa-Lyonnet D, Thomas L, Wierzbicka E, Elder DE, Ming M, Mitra N, Debniak T, Lubinski J, Hocevar M, Novakovic S, Peric B, Skerl P, Hansson J, Hoiom V, Friedman E, Azizi E, Baron-Epel O, Scope A, Pavlotsky F, Cohen-Manheim I, Laitman Y, Harland M, Randerson-Moor J, Laye J, Davies J, Nsengimana J, O'Shea S, Chan M, Gascoyne J, Tucker MA, Goldstein AM, Yang XR. Functional characterization of a multi-cancer risk locus on chr5p15.33 reveals regulation of TERT by ZNF148. Nature Communications 2017, 8, 15034.
    • Ranzani M, Kemper K, Michaut M, Krijgsman O, Aben N, Iyer V, Wong K, Roumeliotis TI, Del Castillo Velasco-Herrera M, Nsengimana J, Turner G, Thompson N, Shahrabi A, Sjoberg M, Rashid M, Speak AO, Grinkevich V, Behan F, Tamborero D, Iorio F, van Dongen S, Bignell GR, Alsinet C, Chen S, Supper E, Dutton-Regester K, Pritchard A, Wong C, Enright A, Newton-Bishop J, McDermott U, Hayward NK, Choudhary JS, Yusa K, Wessels L, Garnett MJ, Peeper D, Adams DJ. A screen for combination therapies in BRAF/NRAS wild type melanoma identifies nilotinib plus MEK inhibitor as a synergistic combination. bioRxiv 2017.
    • Lauss M, Nsengimana J, Staaf J, Newton-Bishop J, Jonsson G. Consensus of Melanoma Gene Expression Subtypes Converges on Biological Entities. Journal of Investigative Dermatology 2016, 136(12), 2502-2505.
    • Jewell R, Elliott F, Laye J, Nsengimana J, Davies J, Walker C, Conway C, Mitra A, Harland M, Cook MG, Boon A, Storr S, Safuan S, Martin SG, Jirstrom K, Olsson H, Ingvar C, Lauss M, Bishop T, Jonsson G, Newton-Bishop J. The clinicopathological and gene expression patterns associated with ulceration of primary melanoma. Pigment Cell and Melanoma Research 2015, 28(1), 94-104.
    • Litchfield K, Sultana R, Renwick A, Dudakia D, Seal S, Ramsay E, Powell S, Elliott A, Warren-Perry M, Eeles R, Peto J, Kote-jarai Z, Muir K, Nsengimana J, Stratton MR, Easton DF, Bishop DT, Huddart RA, Rahman N, Turnbull C. Multi-stage genome-wide association study identifies new susceptibility locus for testicular germ cell tumour on chromosome 3q25. Human Molecular Genetics 2015, 24(4), 1169-1176.
    • Nsengimana J, Laye J, Filia A, Walker C, Jewell R, Van Den Oord JJ, Wolter P, Patel P, Sucker A, Schadendorf D, Jonsson GB, Bishop DT, Newton-Bishop J. Independent replication of a melanoma subtype gene signature and evaluation of its prognostic value and biological correlates in a population cohort. Oncotarget 2015, 6(13), 11683-11693.
    • Litchfield K, Holroyd A, Lloyd A, Broderick P, Nsengimana J, Eeles R, Easton DF, Dudakia D, Bishop DT, Reid A, Huddart RA, Grotmol T, Wiklund F, Shipley J, Houlston RS, Turnbull C. Identification of four new susceptibility loci for testicular germ cell tumour. Nature Communications 2015, 6, 8690.
    • Abbotts R, Jewell R, Nsengimana J, Maloney DJ, Simeonov A, Seedhouse C, Elliott F, Laye J, Walker C, Jadhav A, Grabowska A, Ball G, Patel PM, Newton-Bishop J, Wilson DM, Madhusudan S. Targeting human apurinic/apyrimidinic endonuclease 1 (APE1) in phosphatase and tensin homolog (PTEN) deficient melanoma cells for personalized therapy. Oncotarget 2014, 5(10), 3273-3286.
    • Teo MTW, Dyrskjøt L, Nsengimana J, Buchwald C, Snowden H, Morgan J, Jensen JB, Knowles MA, Taylor G, Barrett JH, Borre M, Ørntoft TF, Bishop DT, Kiltie AE. Next-generation sequencing identifies germline MRE11A variants as markers of radiotherapy outcomes in muscle-invasive bladder cancer. Annals of Oncology 2014, 25(4), 877-883.
    • Ruark E, Seal S, McDonald H, Zhang F, Elliot A, Lau KW, Perdeaux E, Rapley E, Eeles R, Peto J, Kote-Jarai Z, Muir K, Nsengimana J, Shipley J, UK Testicular Cancer Collaboration (UKTCC), Bishop DT, Stratton MR, Easton DF, Huddart RA, Rahman N, and Turnbul C. Identification of nine new susceptibility loci for testicular cancer, including variants near DAZL and PRDM14. Nature Genetics 2013, 45(6), 686-689.
    • Nsengimana J, Bishop DT. Design considerations for genetic linkage and association studies. Methods in Molecular Biology 2012, 850, 237-262.
    • Nsengimana J, Barrett JH. Analysis of genetic interactions involving maternal and offspring genotypes at different loci: power simulation and application to testicular cancer. Genetic Epidemiology 2012, 36, 612-621.
    • Barrett JH, Nsengimana J. Two stage analyses of sequence variants in association with quantitative traits. BMC Proceedings 2011, 5 (suppl 9), S53.
    • König IR, Nsengimana J, Papachristou C, Simonson MA, Wang K, Weisburd J. Multiple Testing in High-Throughput Sequence Data: Experiences from Group 8 of the Genetic Analysis Workshop 17. Genetic Epidemiology 2011, 35 (suppl1), S61-S66.
    • Turnbull C, Rapley EA, Seal S, Pernet D, Renwick A, Hughes D, Ricketts M, Linger R, Nsengimana J, Deloukas P, The UK Testicular Cancer Collaboration, Huddart RA, Bishop DT, Easton DF, Stratton MR, and Rahman N. Variants in the vicinity of sex determination gene DMRT1, and the telomere regulator genes TERT and ATF7IP are associated with testicular germ cell cancer. Nature Genetics 2010, 42(7), 604-607.
    • Jewell R, Conway C, Mitra A, Randerson-Moor J, Lobo S, Nsengimana J, Harland M, Marples M, Edward S, Cook M, Powell B, Boon A, de Kort F, Parker KA, Cree IA, Barrett JH, Knowles MA, Bishop DT, Newton-Bishop J. Patterns of expression of DNA repair genes and relapse from melanoma. Clinical Cancer Research 2010, 16(21), 5211-5221.
    • Mitra A, Conway C, Walker C, Cook M, Powell B, Lobo S, Chan M, Kissin M, Layer G, Smallwood J, Ottensmeier C, Stanley P, Peach H, Chong H, Elliott F, Iles MM, Nsengimana J, Barrett JH, Bishop DT, Newton-Bishop JA. Melanoma sentinel node biopsy and prediction models for relapse and overall survival. Br J Cancer 2010, 103, 1229-1236.
    • Bennett CE, Nsengimana J, Bostock JA, Cymbalista C, Futers TS, Knight BL, McCormack LJ, Prasad UK, Riches K, Rolton D, Scarrott T, Barrett JH, Carter AM. CCAAT/enhancer Binding Protein a, β and d Gene Variants: Associations with Obesity Related Phenotypes in the Leeds Family Study. Diabetes and Vascular Disease Research 2010, 7(3), 195-203.
    • Brown BD, Nsengimana J, Barrett JH, Lawrence RA, Steiner L, Cheng S, Bishop DT, Samani NJ, Ball SG, Balmforth AJ, Hall AS. An evaluation of inflammatory gene polymorphisms in sib-ships discordant for premature coronary artery disease: The GRACE-IMMUNE Study. BMC Medicine 2010, 8, 5.
    • Rice A, Nsengimana J, Simmons IG, Toomes C, Hoole J, Willoughby CE, Cassidy F, Williams GA, George ND, Sheridan E, Young TL, Hunter TI, Barrett BT, Elliott DB, Bishop DT, Inglehearn CF. Replication of the recessive STBMS1 but with dominance inheritance. Investigative Ophthalmology and Visual Science 2009, 50, 3210-3217.
    • Conway C, Mitra A, Jewell R, Randerson-Moor J, Lobo S, Nsengimana J, Edward S, Sanders DS, Cook M, Powell B, Boon A, Elliott F, de Kort F, Knowles MA, Bishop DT, Newton-Bishop J. Gene expression profiling of paraffin embedded primary melanoma using the DASL assay identifies increased osteopontin expression as predictive of survival. Clinical Cancer Research 2009, 15(22), 6939-6946.
    • Rapley EA, Turnbull C, Al Olama AA, Dermitzakis ET, Linger R, Huddart RA, Renwick A, Hughes D, Hines S, Seal S, Morrison J, Nsengimana J, Deloukas P, The UK Testicular Cancer Collaboration, Rahman N, Bishop DT, Easton DF, Stratton MR. A genomewide association study of testicular germ cell tumour. Nature Genetics 2009, 41(7), 807-810.
    • Nsengimana J, Barrett JH. Power, validity, bias and robustness of family-based association analysis methods in the presence of linkage for late onset diseases. Annals of Human Genetics 2008, 72(6), 793-780.
    • Nsengimana J, Barrett JH. Renin–angiotensin system genes and coronary artery calcification. Future Cardiology 2007, 3(6), 587-590.
    • Nsengimana J, Samani NJ, Hall AS, Balmforth AJ, Mangino M, Yuldasheva N, Maqbool A, Braund P, Burton P, Bishop DT, Ball SG, Barrett JH, for the British Heart Foundation Family Heart Study Research Group. Enhanced linkage of a locus on chromosome 2 to premature coronary artery disease in the absence of hypercholesterolemia gfgfd. European Journal of Human Genetics 2007, 15, 313-319.
    • Nsengimana J, Renard H, Goldgar D. Linkage analysis of complex diseases using microsatellites and single nucleotide polymorphisms: application to alcoholism. BMC Genetics 2005, 6(Suppl 1), S10.
    • The BHF Family Heart Study Research Group. A genome wide linkage study of 1933 families affected by premature coronary artery disease: The British Heart Foundation Family Heart Study. American Journal of Human Genetics 2005, 77, 1011-1020.
    • Nsengimana J, Baret P, Haley CS, Visscher PM. Linkage disequilibrium in the domesticated pig. Genetics 2004, 166(3), 1395-1404.
    • Nsengimana J, Baret PV. Linkage disequilibrium and the genetic distance in livestock populations: the impact of inbreeding. Genetics Selection Evolution 2004, 36(3), 281-296.

  • Book Chapter

  • Letter